Overview

Founded in 2008, Castle Biosciences is a leading molecular diagnostics company focused on improving health through innovative tests that guide patient care. Realizing a large unmet clinical need in disease management, we continuously strive to evolve and improve, challenging the status quo with scientific expertise, value insights and robust data development.

Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market five proprietary tests designed to answer clinical questions and address treatment plan challenges facing clinicians in dermatologic cancers, uveal melanoma and Barrett’s esophagus. Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. The TissueCypher® Barrett’s Esophagus test is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus.



Learn more about Castle Biosciences' mission to empower patients and healthcare providers by combining innovation, advanced technologies, and relevant real-world evidence to address critical unmet clinical needs and improve health outcomes.

This behind-the-scenes video offers an inside look at Castle Biosciences' TissueCypher testing process, showcasing how advanced imaging, multiplexed biomarker staining, and AI-driven analysis are utilized to assess a patient's risk of progression from Barrett’s esophagus to esophageal cancer.

Corporate Presentation

Upcoming Events

View All Events

Quarterly Results

View All Financial Results

News

View all news

Annual Report

2024 was another year of strength for Castle. Fueled by our steadfast commitment to improving patient care, we navigated a dynamic reimbursement and regulatory landscape while delivering exceptional performance results for our stockholders. Our team's unwavering passion and collaborative spirit were instrumental in driving us forward, underscoring our strong, people-first mindset which defines our culture and powers our organization.

Continuing our track record of strong and consistent financial performance, we delivered 96,071 total test reports in 2024, an increase of 36% compared to 2023, and full-year revenue of $332 million, representing 51% growth over 2023. Importantly, we believe these exceptional results reflect the growing adoption of our tests among healthcare providers due to the meaningful impact we are making in the lives of patients through our tests that can help improve treatment pathway decisions and, ultimately, outcomes. Download PDF